{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:58:18Z","timestamp":1793865498889,"version":"4.6.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"am","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA266853"],"award-info":[{"award-number":["R37CA266853"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.eprac.2023.06.006","type":"journal-article","created":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T10:22:02Z","timestamp":1687688522000},"page":"705-709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Optimal Management of Insulin in Patients Undergoing 18F-Fluorodeoxyglucose Positron Emission Tomography Scans"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7654-9064","authenticated-orcid":false,"given":"Shivani","family":"Seth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7920-8474","authenticated-orcid":false,"given":"Emily J.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2023.06.006_bib1","article-title":"Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025","volume":"10","author":"Lin","year":"2020","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.eprac.2023.06.006_bib2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","article-title":"Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"8","author":"Kocarnik","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.eprac.2023.06.006_bib3","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.2337\/dc22-0622","article-title":"The National Clinical Care Commission Report to Congress: summary and next steps","volume":"46","author":"Conlin","year":"2023","journal-title":"Diabetes Care"},{"issue":"9087","key":"10.1016\/j.eprac.2023.06.006_bib4","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S0140-6736(97)03062-6","article-title":"UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group","volume":"350","author":"Turner","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2023.06.006_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.919942","article-title":"Closed-loop insulin delivery systems: past, present, and future directions","volume":"13","author":"Templer","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.eprac.2023.06.006_bib6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2337\/dc10-zb01","article-title":"Aspects of insulin treatment","volume":"33","author":"Bloomgarden","year":"2010","journal-title":"Diabetes Care"},{"issue":"23","key":"10.1016\/j.eprac.2023.06.006_bib7","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1001\/jama.2008.824","article-title":"Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis","volume":"300","author":"Barone","year":"2008","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.006_bib8","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1677\/ERC-09-0087","article-title":"Diabetes and cancer","volume":"16","author":"Vigneri","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"23","key":"10.1016\/j.eprac.2023.06.006_bib9","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/jnci\/djg105","article-title":"Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden","volume":"95","author":"Zendehdel","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.eprac.2023.06.006_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S2213-8587(20)30431-9","article-title":"Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records","volume":"9","author":"Pearson-Stuttard","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.006_bib11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00125-022-05854-8","article-title":"Inequalities in cancer mortality trends in people with type 2 diabetes: 20 year population-based study in England","volume":"66","author":"Ling","year":"2023","journal-title":"Diabetologia"},{"issue":"16","key":"10.1016\/j.eprac.2023.06.006_bib12","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1111\/febs.14577","article-title":"Glucose transporters in cancer - from tumor cells to the tumor microenvironment","volume":"285","author":"Ancey","year":"2018","journal-title":"FEBS J"},{"issue":"3","key":"10.1016\/j.eprac.2023.06.006_bib13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1148\/radiology.183.3.1584912","article-title":"Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma","volume":"183","author":"Wahl","year":"1992","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.eprac.2023.06.006_bib14","first-page":"1030","article-title":"FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies","volume":"39","author":"Diederichs","year":"1998","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.eprac.2023.06.006_bib15","first-page":"1","article-title":"Influence of the blood glucose concentration on FDG uptake in cancer--a PET study","volume":"34","author":"Lindholm","year":"1993","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.eprac.2023.06.006_bib16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1095-0397(99)00029-1","article-title":"Diabetes decreases FDG accumulation in primary lung cancer","volume":"2","author":"Torizuka","year":"1999","journal-title":"Clin Positron Imaging"},{"issue":"6","key":"10.1016\/j.eprac.2023.06.006_bib17","first-page":"678","article-title":"Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases","volume":"24","author":"Zimny","year":"1997","journal-title":"Eur J Nucl Med"},{"issue":"2","key":"10.1016\/j.eprac.2023.06.006_bib18","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.eprac.2023.06.006_bib19","first-page":"885","article-title":"Procedure guideline for tumor imaging with 18F-FDG PET\/CT 1.0","volume":"47","author":"Delbeke","year":"2006","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.eprac.2023.06.006_bib20","unstructured":"Paez D, Dondi M. Standard Operating Procedures for PET\/CT: A Practical Approach for Use in Adult Oncology."},{"issue":"6","key":"10.1016\/j.eprac.2023.06.006_bib21","first-page":"1059","article-title":"Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials","volume":"47","author":"Shankar","year":"2006","journal-title":"J\u00a0Nucl Med"},{"issue":"12","key":"10.1016\/j.eprac.2023.06.006_bib23","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1007\/s00259-008-0874-2","article-title":"The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials","volume":"35","author":"Boellaard","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.006_bib24","first-page":"404","article-title":"[18F]FDG-PET scan in patients with fasting hyperglycemia","volume":"60","author":"Belohlavek","year":"2016","journal-title":"Q\u00a0J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eprac.2023.06.006_bib25","unstructured":"Manual, A. On contrast media. (2020)."},{"issue":"1","key":"10.1016\/j.eprac.2023.06.006_bib26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2967\/jnmt.113.132621","article-title":"18F-FDG PET and PET\/CT patient preparation: a review of the literature","volume":"42","author":"Surasi","year":"2014","journal-title":"J\u00a0Nucl Med Technol"},{"issue":"2","key":"10.1016\/j.eprac.2023.06.006_bib27","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1148\/radiol.2018180078","article-title":"Metformin discontinuation prior to FDG PET\/CT: a randomized controlled study to compare 24- and 48-hour bowel activity","volume":"289","author":"Hamidizadeh","year":"2018","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.eprac.2023.06.006_bib28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2967\/jnumed.109.074104","article-title":"Variations in PET\/CT methodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey","volume":"52","author":"Graham","year":"2011","journal-title":"J\u00a0Nucl Med"},{"issue":"6","key":"10.1016\/j.eprac.2023.06.006_bib29","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jacr.2018.09.006","article-title":"Management of diabetes mellitus before 18F-fluorodeoxyglucose PET\/CT: a nationwide patient-centered assessment of approaches to examination preparation","volume":"16","author":"Kaiser","year":"2019","journal-title":"J\u00a0Am Coll Radiol"},{"key":"10.1016\/j.eprac.2023.06.006_bib30","unstructured":"Evangelista L, Rubini G, AMD MG, Gori S. Gestione della glicemia nei pazienti oncologici da sottoporre a FDG PET\/TC (2019)."},{"issue":"2","key":"10.1016\/j.eprac.2023.06.006_bib31","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2967\/jnumed.108.056283","article-title":"Impact of intravenous insulin on 18F-FDG PET in diabetic cancer patients","volume":"50","author":"Roy","year":"2009","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.eprac.2023.06.006_bib32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MNM.0000000000000082","article-title":"Influence of subcutaneous administration of rapid-acting insulin in the quality of (18)F-FDG PET\/CT studies","volume":"35","author":"Garcia","year":"2014","journal-title":"Nucl Med Commun"},{"issue":"2","key":"10.1016\/j.eprac.2023.06.006_bib33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4103\/ijnm.IJNM_151_19","article-title":"Utility of short-acting intravenous insulin therapy in preparation of F-18 fluorodeoxyglucose positron emission tomography computed tomography scan in cancer patients incidentally detected with high blood glucose levels on the day of test","volume":"35","author":"Rallapeta","year":"2020","journal-title":"Indian J Nucl Med"},{"issue":"1","key":"10.1016\/j.eprac.2023.06.006_bib34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13550-019-0480-2","article-title":"Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET\/CT","volume":"9","author":"Pattison","year":"2019","journal-title":"EJNMMI Res"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.006_bib35","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/01.rlu.0000257273.55996.8b","article-title":"No apparent alteration of F-18 FDG biodistribution when injected shortly after insulin glargine","volume":"32","author":"Niederkohr","year":"2007","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1016\/j.eprac.2023.06.006_bib36","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s13300-020-00831-z","article-title":"Evolution of insulin delivery devices: from syringes, pens, and pumps to DIY artificial pancreas","volume":"11","author":"Kesavadev","year":"2020","journal-title":"Diabetes Ther"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X23004482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X23004482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:15:04Z","timestamp":1761516904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X23004482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1530891X23004482"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2023.06.006","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal Management of Insulin in Patients Undergoing 18F-Fluorodeoxyglucose Positron Emission Tomography Scans","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2023.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}